Oncolytics Biotech Inc. · NASDAQ:ONCY

Oncolytics Biotech — Investor Presentation (August 2016)

26 slides from Oncolytics Biotech's investor presentation, August 2016

  1. Slide 1: Corporate Presentation

    Corporate Presentation August 2016

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains certain forward looking statements relating to the Company’s financial results, business prospects, and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on management’s current expectations an

  3. Slide 3: Oncolytics Overview

    Oncolytics Overview Developing REOLYSIN® 400+ issued patents and (oncolytic virus) as a 70+ pending cancer therapeutic applications worldwide Conducted 30+ clinical 1,100+ patients treated; studies in 13 indications strong safety profile Manufacturing $20.41 million total at commercial scale current

  4. Slide 4: What is REOLYSIN?

    What is REOLYSIN®?  A proprietary isolate of wild-type reovirus Serotype 3 Dearing  Non-pathogenic  Most humans show evidence of exposure by adulthood 4

  5. Slide 5: Safety Profile of REOLYSIN

    Safety Profile of REOLYSIN® General Safety  1,100+ patients treated, 1,000+ of these intravenously  No maximum tolerated dose (MTD) reached  Safety profile confirmed in a randomized setting Monotherapy Safety  Mild toxicities (grade 1 or 2) including • Chills • Cough • Sore throat • Fever • Myal

  6. Slide 6: REOLYSIN: Two Mechanisms of Action

    REOLYSIN®: Two Mechanisms of Action 1. In cancer cells with Ras pathway activating mutations (Braf, Kras, Nras, Hras, and EGFR) or p53, REOLYSIN® acts as a directed cytotoxin. 2. REOLYSIN® also interacts with the immune system in at least two known ways, thereby functioning as an immune therapy. 6

  7. Slide 7: Effect of Ras Pathway Activating and/or p53 Mutations on PFS and OS

    Effect of Ras Pathway Activating and/or p53 Mutations on Progression Free Survival and Overall Survival  Randomized Phase II of non-squamous NSCLC patients with treated with pemetrexed and REOLYSIN®.  The test arm patients with Ras pathway activating and/or p53 mutations received greater PFS and O

  8. Slide 8: Effect of Ras Pathway Activating and/or p53 Mutations on PFS and OS

    Effect of Ras Pathway Activating and/or p53 Mutations on Progression Free Survival and Overall Survival 8

  9. Slide 9: Cancer and Metastases

    Cancer and Metastases  Approximately 8.5 million people die from cancer each year, 4 million of them in the developed world.  90% of cancer deaths are due to metastatic disease, primarily in the liver, lung, lymph nodes, and brain.  An agent with specific, demonstrated activity in metastatic dise

  10. Slide 10: REOLYSIN: Effect on Liver Metastases

    REOLYSIN®: Effect on Liver Metastases  REOLYSIN® should have tumour effects on the liver, lymph, lung, and brain metastases in patients based on: 1. Biodistribution patterns; 2. Ability to cross the blood brain barrier in patients with brain metastases; and 3. Genetics. 10

  11. Slide 11: Liver Metastases

    Liver Metastases  REOLYSIN® was shown in single-arm drug combination studies in head and neck cancer patients to markedly reduce liver metastases in an “unusual” manner.  However, single arm study responses must be considered to be anecdotal. 11

  12. Slide 12: Partial Response in Metastatic Liver Tumors – REOLYSIN/Paclitaxel/Carboplatin (Phase 1)

    Partial Response in Metastatic Liver Tumors – REOLYSIN®/Paclitaxel/Carboplatin (Phase 1) Pre-Treatment Post-Cycle 2 Post-Cycle 6 • Diagnosis: Metastatic sinu-nasal carcinoma with marked progression of pelvic and hepatic disease • Prior Treatment: Radiotherapy 12

  13. Slide 13: Partial Response in Metastatic Nasopharyngeal Cancer (Phase 2)

    Partial Response in Metastatic Nasopharyngeal Cancer – REOLYSIN®/Paclitaxel/Carboplatin (Phase 2) Pre-Treatment Post-Cycle 3 • Treatment History: Radiation (2 cycles); cisplatin, gemcitabine/carboplatin, carboplatin/5-FU (6 cycles); docetaxel (3 cycles) • Liver metastases reduced from 59.4 mm at bas

  14. Slide 14: Randomized Tumour-Specific Data in Head and Neck Cancer (REO 018)

    Randomized Tumour-Specific Data: REOLYSIN®/Carboplatin/Paclitaxel Combination in Head and Neck Cancer (REO 018)  Loco-regional patients with or without distal metastases experienced a 23% increased reduction in median total tumour volume in the test arm versus the control arm (median from Kaplan-Me

  15. Slide 15: REOLYSIN and Metastases

    REOLYSIN® and Metastases  REOLYSIN® demonstrated overall metastatic disease tumour reduction in a randomized clinical study.  There is now evidence in a randomized study that REOLYSIN® demonstrates liver metastases specific tumour reduction. 15

  16. Slide 16: IND 210 Colorectal Cancer Study: Randomized Tumor Specific Data

    IND 210 Colorectal Cancer Study: Randomized Tumor Specific Data  Patients were treated with FOLFOX-6/Avastin® plus or minus REOLYSIN®.  Patients in the test arm had a 53% objective overall response rate (n=51) versus 35% in the control arm (n=52) (p = 0.06).  Patients with liver metastases (with

  17. Slide 17: IND 210 Colorectal Cancer Study: Data by Gender

    IND 210 Colorectal Cancer Study: Randomized Tumor Specific Data by Gender  Female patients with or without metastases on the test arm had a 63.2% objective response rate (n=19) versus 23.8% on the control arm (n=21) (p=0.0054).  These patients also experienced a 51% increased reduction in median t

  18. Slide 18: New Colorectal Cancer Study

    New Colorectal Cancer Study  Oncolytics Biotech Inc. has filed for a Phase 2 run- in study of FOLFOX-6/Avastin®/REOLYSIN® and pembrolizumab in female patients with colorectal cancer prescreened for mutations in EGFR, Kras, Mras, Hras, BRAF or p53 that is metastatic to the liver.  Once we confirm t

  19. Slide 19: IND 211 NSCLC Study: PFS and OS by Gender

    IND 211 NSCLC Study: Randomized Progression Free Survival and Overall Survival by Gender  Randomized Phase II of non-squamous NSCLC patients with treated with pemetrexed and REOLYSIN®.  Female patients on the test arm received greater PFS and OS benefit than female patients on the control arm.  M

  20. Slide 20: IND 211 NSCLC Study: PFS and OS by Gender

    IND 211 NSCLC Study: Randomized Progression Free Survival and Overall Survival by Gender 20

  21. Slide 21: Manufacturing

    Manufacturing  Now produced at commercial scale (100L) under cGMP with final formulation  Commercial manufacturing agreement in place with Sigma-Aldrich® Fine Chemicals (SAFC) 21

  22. Slide 22: Patent Portfolio

    Patent Portfolio  More than 400 patents issued worldwide, including 60 US and 20 Canadian  More than 70 pending patent applications worldwide  Issued patent claims for reovirus cover:  Compositions of matter comprising reovirus  Pharmaceutical use of reoviruses to treat neoplasia and cellular p

  23. Slide 23: Corporate & Financial

    C)ncoryrics www.oncolyticsbiotech.com ONC ONCY ONY

  24. Slide 24: Market & Capital Data

    Market & Capital Data (all amounts in CAD) Exchanges OTCQX:ONCYF TSX:ONC FRA:ONY Shares Outstanding (June 30, 2016) 120,233,122 Price Options Outstanding (June 30, 2016) $2.04 7,754,727 (weighted average) Fully Diluted (June 30, 2016) 127,987,849 Total Current Assets (June 30, 2016) $20.41 M 24

  25. Slide 25: Investment Highlights

    Investment Highlights  Conducting first checkpoint inhibitor and REOLYSIN® study in patients with pancreatic cancer  Preparing for registration study  Positive safety data for 1,100+ patients  Strong intellectual property portfolio  More than 400 issued patents worldwide  Manufacturing at comm

  26. Slide 26: Corporate Presentation

    Corporate Presentation August 2016

Oncolytics Biotech — Investor Presentation (August 2016) on 6ix